Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevacizumab + fosbretabulin
- Development stage
- Unknown
- Lead developer
- OXiGENE
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This combination therapy consists of bevacizumab, a humanized monoclonal antibody targeting vascular endothelial growth factor (VEGF), and fosbretabulin (CA4P), a vascular disrupting agent (VDA). Bevacizumab acts as an anti-angiogenic agent by neutralizing VEGF-A, thereby preventing the formation of new tumor blood vessels. Fosbretabulin, a prodrug of combretastatin A-4, targets existing tumor vasculature by binding to the colchicine site of beta-tubulin, leading to microtubule depolymerization and the rapid collapse of established tumor vessels. The combination is being evaluated for its potential synergistic effects in recurrent high-grade gliomas, where the anti-angiogenic properties of bevacizumab may complement the vascular-disrupting activity of fosbretabulin to improve clinical outcomes.
- Brand names
- Avastin
- Other names
- bevacizumab + CA4Pbevacizumab + fosbretabulin tromethaminefosbretabulin + bevacizumab
02
Targets
VEGFA (Vascular endothelial growth factor A)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on bevacizumab + fosbretabulin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevacizumab + fosbretabulin.